Company intelligence / Profile preview
C4X Discovery
Manchester, England, United Kingdomc4xdiscovery.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
C4X Discovery has one candidate in clinical development through Indivior. Their NRF-2 Activator program was licensed to AstraZeneca, and their α4β7 integrin inhibitor program for IBD has shown improved activity at lower doses compared to competitor compounds in pharmacodynamic models after oral dosing.
- Therapeutic areas
- GastroenterologyPsychiatryImmunologyHematologyOncologyNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Beyond the preview
Go deeper on C4X Discovery.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C4X Discovery.